NCT04422652View on ClinicalTrials.gov

Combination of Novel Therapies for CKD Comorbid Depression

PHASE2RecruitingINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Chronic Kidney DiseasesMajor Depressive Disorder
Interventions
DRUG

Bupropion

Bupropion is an anti-depressant medication.

BEHAVIORAL

Behavioral activation therapy

Brief behavioral activation treatments administered via video tele-conferencing.

DRUG

Placebo

Double-blind placebo.

OTHER

Clinical Management

Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.

Trial Locations (4)

75235

RECRUITING

Parkland Health and Hospital System, Dallas

75390

RECRUITING

UT Southwestern and Affiliates, Dallas

98195

RECRUITING

University of Washington, Seattle

11794-8430

NOT_YET_RECRUITING

Stony Brook University Medical Center, Stony Brook

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Stony Brook University

OTHER